Pyxis Oncology, Inc.
PYXSNASDAQHealthcare● Active
$1.70
$-0.09(-4.78%)
Market Cap$107387539
P/E Ratio—
52W High$5.55
52W Low$0.97
Pyxis Oncology, Inc. (PYXS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PYXS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.37
Est. -$0.35 · -5.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
PYXS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.35 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.35 | -$0.37 | -5.7% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.35 | -$0.29 | +17.1% | $0.01B | $0.00B | +8730.4% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$0.36 | -$0.35 | +2.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.36 | -$0.30 | +16.7% | $0.00B | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.29 | -$0.35 | -20.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$0.33 | -$0.32 | +3.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.32 | -$0.35 | -9.4% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.35
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.35
EPS Surpr.
-5.7%
Revenue
—
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.29
EPS Est.
-$0.35
EPS Surpr.
+17.1%
Revenue
$0.01B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.36
EPS Surpr.
+2.8%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.36
EPS Surpr.
+16.7%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.29
EPS Surpr.
-20.7%
Revenue
—
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.33
EPS Surpr.
+3.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.35
EPS Est.
-$0.32
EPS Surpr.
-9.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.40 | $-0.40 | $-0.40 | 3 |
| Q3 FY2028 | $-0.41 | $-0.41 | $-0.41 | 3 |
| Q2 FY2028 | $-0.40 | $-0.40 | $-0.40 | 3 |
| Q1 FY2028 | $-0.40 | $-0.40 | $-0.40 | 3 |
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 2 |
| Q3 FY2027 | $-0.27 | $-0.27 | $-0.27 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -5.7% | $2.62 | $2.21 | -15.65% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +17.1% | $1.47 | $1.42 | -3.40% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +2.8% | $3.56 | $3.81 | +7.02% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +16.7% | $1.07 | $1.13 | +5.61% |
| ▼ Q2 FY2025 | May 15, 2025 | -20.7% | $1.07 | $1.11 | +3.74% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +3.0% | $1.16 | $1.06 | -8.62% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -9.4% | $4.74 | $4.62 | -2.53% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +12.1% | $3.47 | $3.36 | -3.17% |
Q2 FY2026-15.65%
Report Date
May 14, 2026
EPS Beat/Miss
-5.7%
Price Before
$2.62
Price After
$2.21
Q1 FY2026-3.40%
Report Date
Mar 23, 2026
EPS Beat/Miss
+17.1%
Price Before
$1.47
Price After
$1.42
Q4 FY2025+7.02%
Report Date
Nov 3, 2025
EPS Beat/Miss
+2.8%
Price Before
$3.56
Price After
$3.81
Q3 FY2025+5.61%
Report Date
Aug 14, 2025
EPS Beat/Miss
+16.7%
Price Before
$1.07
Price After
$1.13
Q2 FY2025+3.74%
Report Date
May 15, 2025
EPS Beat/Miss
-20.7%
Price Before
$1.07
Price After
$1.11
Q1 FY2025-8.62%
Report Date
Mar 18, 2025
EPS Beat/Miss
+3.0%
Price Before
$1.16
Price After
$1.06
Q4 FY2024-2.53%
Report Date
Nov 12, 2024
EPS Beat/Miss
-9.4%
Price Before
$4.74
Price After
$4.62
Q3 FY2024-3.17%
Report Date
Aug 14, 2024
EPS Beat/Miss
+12.1%
Price Before
$3.47
Price After
$3.36
Avg Beat Reaction-0.51%
Avg Miss Reaction-4.81%
Beat Rate5 / 8 quarters
Largest Move-15.65% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PYXS ends December
Pyxis Oncology, Inc. (PYXS) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.37 — missing the analyst consensus of $-0.35 by -5.7%. The next PYXS earnings date is expected around September 1, 2026.
Each quarter, investors track PYXS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PYXS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PYXS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PYXS earnings · 5 questionsPyxis Oncology, Inc.'s next earnings report is expected around September 1, 2026. PYXS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PYXS historically reports after market close (AMC).
PYXS earnings datewhen is PYXS earningsPYXS next earnings datewhen does PYXS report earningsPYXS earnings calendar
▸ Source: FMP · Pyxis Oncology, Inc. SEC filings · US GAAP · Pyxis Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026